CY1117433T1 - Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna - Google Patents

Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna

Info

Publication number
CY1117433T1
CY1117433T1 CY20161100261T CY161100261T CY1117433T1 CY 1117433 T1 CY1117433 T1 CY 1117433T1 CY 20161100261 T CY20161100261 T CY 20161100261T CY 161100261 T CY161100261 T CY 161100261T CY 1117433 T1 CY1117433 T1 CY 1117433T1
Authority
CY
Cyprus
Prior art keywords
compounds
group
drug release
targeted drug
sirna activity
Prior art date
Application number
CY20161100261T
Other languages
Greek (el)
English (en)
Inventor
C Nagarajan Sridhar
Priya Karmali
Yoshiro Niitsu
Joseph E Payne
Zheng Hou
John A Gaudette
Victor Knopov
Richard P Witte
Mohammad Ahmadian
Loren A Perelman
Yasunobu Tanaka
Violetta Akopian
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of CY1117433T1 publication Critical patent/CY1117433T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CY20161100261T 2011-06-08 2016-03-31 Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna CY1117433T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494710P 2011-06-08 2011-06-08
US201161494840P 2011-06-08 2011-06-08
EP12728010.5A EP2718261B1 (en) 2011-06-08 2012-06-08 Compounds for targeting drug delivery and enhancing sirna activity

Publications (1)

Publication Number Publication Date
CY1117433T1 true CY1117433T1 (el) 2017-04-26

Family

ID=46317540

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100261T CY1117433T1 (el) 2011-06-08 2016-03-31 Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna
CY20191100937T CY1123807T1 (el) 2011-06-08 2019-09-05 Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100937T CY1123807T1 (el) 2011-06-08 2019-09-05 Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna

Country Status (20)

Country Link
EP (2) EP2998289B1 (enExample)
JP (3) JP5873553B2 (enExample)
KR (3) KR102038300B1 (enExample)
CN (3) CN107043334B (enExample)
AU (2) AU2012267467B8 (enExample)
CA (2) CA3094645C (enExample)
CY (2) CY1117433T1 (enExample)
DK (2) DK2718261T3 (enExample)
ES (2) ES2743540T3 (enExample)
HR (1) HRP20191463T8 (enExample)
HU (1) HUE045821T2 (enExample)
LT (1) LT2998289T (enExample)
PL (2) PL2998289T3 (enExample)
PT (1) PT2998289T (enExample)
RS (1) RS59380B1 (enExample)
RU (2) RU2769872C2 (enExample)
SI (1) SI2998289T1 (enExample)
SM (1) SMT201900523T1 (enExample)
TW (2) TWI712422B (enExample)
WO (1) WO2012170952A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933233A (zh) * 2010-06-17 2013-02-13 日东电工株式会社 肾纤维化处理剂
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CN103906503B (zh) * 2011-11-04 2016-12-14 日东电工株式会社 用于无菌制备脂质-核酸颗粒的单次使用系统
BR112014030714B1 (pt) * 2012-06-08 2020-12-22 Nitto Denko Corporation composto de lipídeo ionizável, composição, veículo de fármaco e formulação farmacêutica
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
KR102095085B1 (ko) 2013-11-18 2020-03-31 아크투루스 쎄라퓨틱스, 인크. Rna 전달을 위한 이온화가능한 양이온성 지질
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
ES2821966T3 (es) 2014-04-02 2021-04-28 Nitto Denko Corp Molécula de direccionamiento derivada de RBP y utilización de la misma
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
EP2966068A1 (en) * 2014-07-08 2016-01-13 Incella GmbH Synthesis and use of amino lipids
CN104174034A (zh) * 2014-08-20 2014-12-03 南京大学 肝星状细胞靶向的基因药物输送载体及其制备方法和应用
US9855345B2 (en) * 2014-10-30 2018-01-02 Delta-Fly Pharma, Inc. Method for producing lipoplex for topical administration and antitumor agent using such lipoplex
LT3221293T (lt) * 2014-11-18 2023-03-27 Arcturus Therapeutics, Inc. Jonizuojamas katijoninis lipidas, skirtas rnr pristatymui
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
KR102659774B1 (ko) * 2015-06-24 2024-04-23 닛토덴코 가부시키가이샤 이온화성 화합물 및 조성물 및 그 용도
CN116640316A (zh) * 2015-09-14 2023-08-25 得克萨斯州大学系统董事会 亲脂阳离子树枝状聚合物及其用途
CN105194689A (zh) * 2015-10-10 2015-12-30 湖南中楚博生物科技有限公司 一种基于siRNA的双偶联复合物
CN114656378A (zh) 2016-05-16 2022-06-24 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
PL3458074T3 (pl) * 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
JP6833456B2 (ja) 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
JP7178715B2 (ja) 2017-05-23 2022-11-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ジメチル－ノナテトラエニル－トリメチル－シクロヘキシル化合物およびその使用
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3662913A4 (en) 2017-08-04 2021-06-30 Kyowa Kirin Co., Ltd. Nucleic-acid-containing lipid nanoparticles
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
JP7208911B2 (ja) 2017-10-11 2023-01-19 日東電工株式会社 核酸分子発現の調節
KR102751412B1 (ko) * 2017-11-06 2025-01-09 닛토덴코 가부시키가이샤 생물학적 활성 분자의 전달을 위한 융합성 화합물
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
CN116172975B (zh) 2018-06-08 2025-03-28 富士胶片株式会社 脂质颗粒、包含该脂质颗粒的核酸药物以及核酸递送用组合物
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
JP7453145B2 (ja) * 2018-08-22 2024-03-19 日東電工株式会社 Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強
AU2019336679B2 (en) 2018-09-04 2025-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for organ specific delivery of nucleic acids
WO2020051220A1 (en) 2018-09-04 2020-03-12 The Board of the Regents of the University of Texas System Compositions and methods for organ specific delivery of nucleic acids
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN110124049B (zh) * 2019-04-29 2023-09-22 大连医科大学 聚乙二醇化芬维a胺前体药物及其用途
CA3143865A1 (en) 2019-06-07 2020-12-10 Fujifilm Corporation Lipid composition
KR102228271B1 (ko) 2019-07-16 2021-03-17 한국과학기술연구원 항암활성을 갖는 면역조절 단백질-siRNA 복합체
CN111248152A (zh) * 2020-03-17 2020-06-09 上海市中医医院 一种肝硬化腹水动物模型及其构建方法
BR112022021381A2 (pt) * 2020-04-23 2022-12-06 Purdue Research Foundation Compostos para o tratamento de sars
KR102361479B1 (ko) * 2020-06-18 2022-02-11 고려대학교 산학협력단 ｓｉＲＮＡ의 생성 및 기능 증진 활성을 갖는 ＣＭＴＲ１의 신규용도
WO2021262746A1 (en) * 2020-06-24 2021-12-30 Bristol-Myers Squibb Company Process for synthesizing lipids
JP2023532011A (ja) * 2020-06-24 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 標的分子の合成方法
JP2023532014A (ja) * 2020-06-24 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー カチオン性脂質の合成方法
IL300404A (en) * 2020-08-06 2023-04-01 Modernatx Inc Methods for preparing fat nanoparticles
WO2022034946A1 (ko) 2020-08-14 2022-02-17 한국과학기술연구원 항암활성을 갖는 면역조절 단백질-siRNA 복합체
CN114391008B (zh) * 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN114306278A (zh) * 2021-12-30 2022-04-12 上海纳米技术及应用国家工程研究中心有限公司 一种EV装载CPP-siRNA纳米颗粒的制备方法及其产品和应用
CN114805113B (zh) * 2022-01-22 2023-09-15 苏州天澜生物材料科技有限公司 一种安全高效的可降解脂质纳米颗粒及其制备方法和应用
CN114522244B (zh) * 2022-01-28 2023-09-01 浙江大学医学院附属第四医院 视黄酸修饰的lytac分子及其制备方法和应用
US20250197865A1 (en) 2022-03-03 2025-06-19 Kyushu University, National University Corporation Pharmaceutical composition for treatment or prevention of fibrotic disease
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024160829A1 (en) * 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
EP4480943A1 (en) * 2023-06-22 2024-12-25 Oz Biosciences New class of lipids for delivering active ingredients into cells
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN117185942B (zh) * 2023-07-04 2025-09-12 清华大学 一种可用于靶向肺部递送广谱中和抗体的脂质纳米颗粒及其制备方法与应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6189286A (ja) * 1984-10-08 1986-05-07 Tokuyama Soda Co Ltd 液晶組成物
JPS61136584A (ja) * 1984-12-07 1986-06-24 Tokuyama Soda Co Ltd 液晶組成物
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
JP3029354B2 (ja) * 1992-12-22 2000-04-04 三菱電機株式会社 ディジタルビデオ信号符号化装置および復号化装置
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19641672A1 (de) * 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
ATE359829T1 (de) * 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
EP1608380A2 (en) * 2003-03-31 2005-12-28 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
JP2006254877A (ja) * 2005-03-18 2006-09-28 Fukuoka Prefecture 糖脂質を含んだキャリア及びそれを用いた遺伝子導入法
JP5777846B2 (ja) * 2005-06-15 2015-09-09 マサチューセッツ インスティテュート オブ テクノロジー アミン含有脂質およびその使用
EP2034019B1 (en) * 2006-06-30 2014-08-20 Hokkaido System Science Co., Ltd. Composition for nucleic-acid introduction
JP2010527914A (ja) 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
US8003621B2 (en) * 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
RU2505315C2 (ru) * 2008-07-30 2014-01-27 Нитто Денко Корпорейшн Носители лекарственных средств
KR20160095209A (ko) * 2008-09-12 2016-08-10 닛토덴코 가부시키가이샤 섬유증 질환의 조영제
CN102292069B (zh) * 2008-11-26 2014-07-30 中外制药株式会社 囊泡制剂
US20120178806A1 (en) * 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
JP6301742B2 (ja) * 2014-06-05 2018-03-28 ヨシモトポール株式会社 鋼管ポールおよびその設置方法

Also Published As

Publication number Publication date
EP2718261A2 (en) 2014-04-16
KR102029654B1 (ko) 2019-10-08
CA3094645C (en) 2023-01-03
AU2017203075B2 (en) 2019-02-07
RU2013158456A (ru) 2015-07-20
AU2012267467B2 (en) 2017-06-01
SMT201900523T1 (it) 2019-11-13
AU2017203075A1 (en) 2017-06-01
CN107043334B (zh) 2020-06-16
HUE045821T2 (hu) 2020-01-28
DK2718261T3 (en) 2016-03-29
AU2012267467A8 (en) 2017-06-15
WO2012170952A2 (en) 2012-12-13
KR20180134424A (ko) 2018-12-18
CA3094645A1 (en) 2012-12-13
WO2012170952A9 (en) 2013-02-21
TW201313256A (zh) 2013-04-01
TWI712422B (zh) 2020-12-11
TWI569814B (zh) 2017-02-11
EP2998289A1 (en) 2016-03-23
KR102038300B1 (ko) 2019-10-31
JP5873553B2 (ja) 2016-03-01
JP2018065804A (ja) 2018-04-26
ES2743540T3 (es) 2020-02-19
EP2998289B1 (en) 2019-08-07
PL2718261T3 (pl) 2016-08-31
CA2837101C (en) 2020-12-15
RU2017135548A (ru) 2019-02-08
CN103857654A (zh) 2014-06-11
LT2998289T (lt) 2019-10-25
CN107082747A (zh) 2017-08-22
CN103857654B (zh) 2017-03-15
WO2012170952A4 (en) 2013-05-30
KR20140033492A (ko) 2014-03-18
AU2012267467B8 (en) 2017-06-15
EP2718261B1 (en) 2016-02-24
RS59380B1 (sr) 2019-11-29
CY1123807T1 (el) 2021-10-29
RU2017135548A3 (enExample) 2021-01-14
RU2632888C2 (ru) 2017-10-11
KR20180134425A (ko) 2018-12-18
JP6590888B2 (ja) 2019-10-16
CN107043334A (zh) 2017-08-15
JP2014529328A (ja) 2014-11-06
HRP20191463T1 (hr) 2019-11-15
PL2998289T3 (pl) 2020-01-31
DK2998289T3 (da) 2019-09-16
PT2998289T (pt) 2019-09-19
WO2012170952A3 (en) 2013-04-11
TW201711706A (zh) 2017-04-01
AU2012267467A1 (en) 2014-01-16
HRP20191463T8 (hr) 2020-02-21
JP2016153477A (ja) 2016-08-25
KR102029657B1 (ko) 2019-10-08
ES2570184T3 (es) 2016-05-17
CA2837101A1 (en) 2012-12-13
RU2769872C2 (ru) 2022-04-07
JP6232083B2 (ja) 2017-11-15
CN107082747B (zh) 2020-11-20
SI2998289T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
CY1117433T1 (el) Ενωσεις για στοχευμενη απελευθερωση φαρμακου και ενισχυση δραστικοτητας sirna
CY1121416T1 (el) Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων
CY1121402T1 (el) Παρασιτοκτονες συνθεσεις οι οποιες περιλαμβανουν εναν δραστικο παραγοντα ισοξαζολινης, μεθοδοι και χρησεις αυτων
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1121047T1 (el) Ενωσεις αμιδιου για τη θεραπεια toy hiv
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1122125T1 (el) Υποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων
UY30339A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos
CY1121776T1 (el) C17-αλκανοδιυλιο και παραγωγα αλκενοδιυλιου του ολεανολικου οξεος και μεθοδοι χρησης αυτων
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EA201400247A1 (ru) Сельскохозяйственная и садоводческая фунгицидная композиция
UY33227A (es) Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CO6680607A2 (es) Métodos para la preparación de profármacos de fosforamidato diastereoméricamente puros
MX2019012280A (es) Composiciones dirigidas.
MX2018012460A (es) Composiciones de conjugados de acido nucleico dirigido.
CY1119762T1 (el) C-17-ετεροαρυλικα παραγωγα ελαιολικου οξεος και μεθοδοι χρησης αυτων
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
CY1118869T1 (el) Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου
MX2018005115A (es) Derivados de heterociclos biciclicos condensados como agentes de control de plagas.
CY1124933T1 (el) Κυτταροτοξικες και αντι-μιτωτικες ενωσεις και μεθοδοι χρησης αυτων
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1120682T1 (el) Ενωσεις για την προστασια κυτταρων
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos